Both the PGA (Patient-derived Gene expression-informed Anticancer drug efficacy) and biomarker testing (or companion diagnostics) offer distinct advantages, making them formidable technologies in their own right. The biomarker testing with its NGS-informed targeted therapy features, advanced bioinformatics, and cutting-edge tumor genome profiling systems, excels in modern, networked clinical decision-making. Meanwhile, the PGA, known for its versatility, quick turnaround, low cost, and powerful drug efficacy/response prediction capabilities, remains a patient-tested gene-to-drug technology capable of screening over 700 existing cancer drugs in a single run.

For companies, the decision to potentially implement PGA could mark a significant expansion in its precision treatment selection capabilities, integrating it with current precision oncology testing workup. On the other hand, the biomarker testing, already in service with some molecular laboratories, continues to be a reliable and effective assay, offering a proven platform tailored to patients’ clinical needs. Yet, here is the real-life situation of today’s precision oncology biomarker testing: Apart from the few glaringly obvious actionable mutations, most end up receiving the blanket “mutation not detected” label, effectively leaving patients without any more treatment answers than when they came into the clinic to be sequenced as precious time ticks away.

Since its debut, PGA has been the subject of attention and inquiry, aimed at developing a much cheaper, quicker and more "generalized" drug efficacy/response prediction for patient non-responders (who are excluded from targeted therapy). It has also begun clinical tests and was selected by a Taiwanese company to test the concept of a "certifiable but non-certified" testing platform, which aims to reduce the regulatory burdens for the certification of a laboratory developed test.

Much more than a laboratory developed test (LDT), PGA offers a real-time, gene-to-drug mapping capability. The platform can smoothly integrate a patient’s own gene signature, enhancing and improving therapeutic efficacies and responses. Decision-making time is shortened from weeks down to days – which could save lives by giving early warnings and actionable options to patients in harm’s way.

The PGA solution is built on a solid foundation of experience and expertise, with no equivalent on the market.

OncoDxRx’s PGA is delivering the promise of precision theranostics today with a game-changing solution that covers prediction, personalization, decision and action with a fit-for-purpose user experience.